Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
ClinicalTrials.gov Identifier:
NCT01834001
First received: April 13, 2013
Last updated: May 3, 2014
Last verified: January 2014
  Purpose

Background:

- Radiation is a common treatment for prostate cancer. It helps damage tumor cells and causes them to die. Radiation can be effective, but some tumors may be harder to treat with radiation or even with surgery. This happens to a small number of men who have either radiation or surgery for prostate cancer. Most men who have these hard-to-treat tumors do not know if the tumor has recurred only in the prostate or has spread to another area. Also, men whose prostate cancer has recurred only after radiation may have different treatment options. This study will use improved imaging studies to better understand why some men do not respond as well to initial radiation treatments.

Objectives:

- To use detailed imaging studies to look at the results of local radiation therapy for prostate cancer.

Eligibility:

  • Men at least 18 years of age who are scheduled to have radiation for prostate cancer.
  • Men at least 18 years of age whose prostate cancer has returned after earlier treatments.

Design:

  • All participants will have a medical history and physical exam. Blood and urine samples will be collected. Imaging studies will be used to evaluate the cancer at the start of the study.
  • All participants will have an initial full magnetic resonance imaging (MRI) scan of the prostate. Tumor and healthy tissue samples will be collected.
  • Those whose cancer has recurred after treatment will discuss possible treatment options with the study doctors.
  • Participants who are scheduled to have radiation will have radiation therapy. This will be given according to the current standard of treatment.
  • After radiation, participants will have regular follow-up tests and imaging studies. They will have another full MRI scan 6 months after the end of radiation treatment.

Condition
Prostatic Neoplasms
Prostate Cancer

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • To determine the rate of local recurrence in patients with prostate cancer treated with radiotherapy using multiparametric prostate MR guided and standard biopsies. [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 190
Study Start Date: April 2013
Estimated Study Completion Date: February 2021
Estimated Primary Completion Date: February 2021 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA: men with untreated prostate cancer

2.1.1.1 Patients must have histologically or cytologically confirmed prostate cancer. The outside pathology report is acceptable for study entry. Every effort will be made to acquire the outside pathology slides to be confirmed by the Laboratory of Pathology, NCI

2.1.1.2 Intermediate or high risk prostate cancer (clinical tumor stage T2b or higher, Gleason 7 or higher, or PSA greater than 10). Previously obtained MR imaging may be used for clinical T staging (extracapsular extension, seminal vesicle invasion).

2.1.1.3 No prior local therapy (prostatectomy, radiation, cryotherapy) or hormonal therapy for prostate cancer.

2.1.1.4 Age greater than or equal to18 years.

2.1.1.5 ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 60%).

2.1.1.6 Radiotherapy is planned as definitive therapy for prostate cancer. For patients not treated at NCI ROB patients must have a radiation oncologist who is willing to collaborate with the ROB and provide documentation of treatment.

2.1.1.7 Ability of subject to understand and the willingness to sign a written informed consent document.

INCLUSION CRITERIA: for men with presumed prostate cancer relapse

2.1.2.1 Patients must have a history of histologically or cytologically confirmed prostate cancer. The outside pathology report is acceptable for study entry. Every effort will be made to acquire the outside pathology slides to be confirmed by the Laboratory of Pathology, NCI

2.1.2.2 Age greater than or equal to18 years.

2.1.2.3 ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 60%, see Appendix A, Section 0).

2.1.2.4 Radiotherapy (external beam irradiation alone or in combination with hormonal therapy and/or brachytherapy) was delivered as definitive therapy for prostate cancer and documentation is available.

2.1.2.5 Evidence of prostate cancer recurrence (biochemical relapse by the Phoenix definition, enlarging palpable prostatic abnormality, imaging evidence strongly suggestive of local failure)

2.1.2.6 Ability of subject to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA

2.1.3.1 Patients unable to tolerate MRI (patients with pacemakers, cerebral aneurysm clips, shrapnel injuries, or other implantable electronic devices or metal not compatible with MRI).

2.1.3.2 Evidence of metastases (pelvic lymph node involvement is not an exclusion criteria)

2.1.3.3 Patients with coagulopathies who are at increased risk for bleeding or on active anticoagulation therapy (platelets less than 100,000 per mm^3 or PT/PTT greater than 1.5 times the upper normal limit (UNL). Patients are eligible if the underlying cause is correctable.

2.1.3.4 Subjects weighing greater than 136kg (weight limit for scanner)

2.1.3.5 Patients with active urinary tract infections

2.1.3.6 Patients with renal insufficiency with a GFR less than 30, due to the fact that they will not be able to undergo gadolinium enhanced MRI

2.1.3.7 Uncontrolled illness or comorbidity that in the judgment of the PI would preclude participation in the study

2.1.3.8 Hepatitis B or Hepatitis C active infection

2.1.3.9 HIV-positive patients are ineligible because HIV is known to increase radiation toxicity and may result in under-dosing or alterations in the treatment plan that would alter the likelihood of local recurrence. Appropriate studies will be undertaken in HIV positive patients when indicated.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01834001

Contacts
Contact: Deborah S McNally, R.N. (301) 496-5457 cooleyd@nih.gov
Contact: Deborah E Citrin, M.D. (301) 496-5457 citrind@mail.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937      
Sponsors and Collaborators
Investigators
Principal Investigator: Deborah E Citrin, M.D. National Cancer Institute (NCI)
  More Information

Additional Information:
Publications:
Responsible Party: National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
ClinicalTrials.gov Identifier: NCT01834001     History of Changes
Other Study ID Numbers: 130119, 13-C-0119
Study First Received: April 13, 2013
Last Updated: May 3, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
MRI
Prostate Cancer
MRI-Guided Biopsy
Radiation
Biochemical Failure

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on September 18, 2014